• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
186845 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
" a9 f: Q& X9 `8 O0 G
+ a8 ^6 R4 n& E1 s: }2 y! e7 ?7 R/ `
( {' F( `/ x% C) N( xSub-category:
& P0 }7 F4 z6 U( n3 M4 TMolecular Targets
  }9 F, W) W  g1 P- P9 P9 ~
+ ?8 h" P1 x5 M( B/ k7 k" c; I( N2 `; M- m! |  r/ p3 Q9 X6 h' }
Category:
- I* Q% T8 X( Z3 D5 n* H) s) JTumor Biology $ C& a2 c- n0 x( y' {
5 t3 O7 x! C" |* U
; E8 i5 C0 O$ k' [+ b* l8 @8 ~8 w
Meeting:
$ [' M2 p) v% H2011 ASCO Annual Meeting
0 z( t' ~7 q* Q6 t7 M8 l: g3 }' F7 p1 a0 `' Y; h
1 J' A. g' w! B- ?7 K
Session Type and Session Title:
- d5 L) m9 l# C8 g/ f, q- FPoster Discussion Session, Tumor Biology
- V% n0 x% B- w2 m$ u" [. z% k% ]* [) _4 Q2 X0 ^' M

6 A) c" g5 O2 T" PAbstract No:
. l- U- B  `6 `  g) K10517 " U1 t7 e. R! r( l$ B8 v1 F8 z

, _& s; Y9 A) _0 D! @7 @0 {
7 l* \- ~* q* E; C8 ^Citation:
* i0 d- G& e! o. g! j3 M+ _J Clin Oncol 29: 2011 (suppl; abstr 10517) ' q9 m$ N, ~* q* a3 f7 P( v) r
  A+ T5 V$ z4 x) _  h3 ]( X

0 Z% L* Q. J& a3 k$ r$ XAuthor(s):
  x0 f7 V/ T# |J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 1 H# W0 [  ^+ S$ a; e% D* o7 C
4 C* f& Q/ D" t/ M
4 v0 X0 `4 w+ ]

0 U5 r; n/ G0 i' T9 W; |Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 V8 V+ i$ [  [4 t7 z
$ ^% O* X6 ?' Z; D3 B* S+ }( C
Abstract Disclosures
6 H* |. k& c& I+ {/ Y
& L  a* S4 v8 Y+ T1 Y5 xAbstract:6 t1 b  T' A  {4 D4 l5 T$ h: \1 ?
$ n  A; K) E4 S, ~# s

  k2 ]6 V" k! o4 m; J) VBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.  w0 M0 e3 B& P

% Y- D1 z$ k! m% C & z! L# w7 A9 x# r' x
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
0 Z1 a$ i( h% R5 O2 ?& o0 O没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

0 a( x( P- G' U2 h* u9 W* o化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
1 o0 e) D. X1 ?  |易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。. U8 r& |# m( l: U2 }6 b6 X2 X% A. {
ALK一个指标医院要900多 ...

9 L# U+ |0 P" v. A8 ~; W平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?: Z' |' d1 C: E: U
: _- C2 f$ Q/ k5 w( F
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表